跳至主要内容
临床试验/NCT00101738
NCT00101738已完成3 期

Study to Investigate the Clinical Outcomes of Different Regimens of Myfortic® in De Novo Kidney Tx Pts Using Simulect® and Neoral® With or Without Steroids

Novartis Pharmaceuticals85 个研究点 分布在 12 个国家目标入组 342 人开始时间: 2003年3月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
342
试验地点
85
主要终点
Calculated glomerular filtration rate after 12 months treatment

研究概览

简要总结

The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females aged 18 to 75 years.
  • Recipients of first, heart-beating cadaveric, living unrelated or living related non-HLA identical donor kidney transplant, treated with Simulect® and Neoral® as primary immunosuppression.

排除标准

  • Second or subsequent kidney transplant or multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any other organ.
  • Kidneys from non-heart beating donors or HLA identical living related donors.
  • ABO incompatibility against the donor.

结局指标

主要结局

Calculated glomerular filtration rate after 12 months treatment

次要结局

  • Incidence of death, graft loss, biopsy-proven acute rejection after 3 and 12 months.
  • Patient and graft survival after 12 months.
  • Incidence of AEs and SAEs after 3 and 12 months.
  • Blood pressure, lipids and glucose profiles after 3 and 12 months.
  • Percentage of patients free of steroids at 12 months

研究者

申办方类型
Industry

研究点 (85)

Loading locations...

相似试验

Freedom Study: Myfortic in Kidney Transplant Patients | 临床试验